Double-Blind, Placebo-Controlled Study of Modafinil for Fatigue and Cognition in Schizophrenia Patients Treated With Psychotropic Medications
J Clin Psychiatry 2005;66(7):839-843
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: To assess the effects of modafinil on
fatigue, symptoms, attention, working memory, and executive
functioning in schizophrenia patients treated with psychotropic
Method: Twenty-four patients with a DSM-IV
diagnosis of schizophrenia or schizoaffective disorder (10 men
and 14 women) were randomly assigned to modafinil up to 200 mg a
day (N = 13) or placebo (N = 11) as an adjunct therapy in an 8-week,
double-blind, placebo-controlled study. Data were collected from
May 18, 2001 to September 11, 2003.
Results: Four subjects terminated the study
early, including one because of worsening of psychosis during the
first week taking modafinil. In the modafinil (N = 10) and placebo
(N = 10) groups, fatigue improved significantly over time
(p < .01), but there were no differences between groups on
changes in fatigue, positive and negative symptoms, or cognition.
Conclusion: Fatigue improved in both groups, and
there were no differences between groups on changes in fatigue,
symptoms, attention, working memory, or executive functioning.
Lack of differences between groups may be due to small sample
size or possible regression to the mean in the placebo group.